Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis
Author:
Affiliation:
1. Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts.
Publisher
Mary Ann Liebert Inc
Subject
Drug Discovery,Genetics,Molecular Biology,Molecular Medicine,Biochemistry
Link
https://www.liebertpub.com/doi/pdf/10.1089/nat.2019.0796
Reference29 articles.
1. Mechanisms of gene silencing by double-stranded RNA
2. RNA interference is mediated by 21- and 22-nucleotide RNAs
3. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
4. GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics
5. Lipid Nanoparticle Systems for Enabling Gene Therapies
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Frameworks for transformational breakthroughs in RNA-based medicines;Nature Reviews Drug Discovery;2024-05-13
2. RNAi-based drug design: considerations and future directions;Nature Reviews Drug Discovery;2024-04-03
3. Recent Progress in the Development and Clinical Application of New Drugs for Transthyretin Cardiac Amyloidosis;Journal of Cardiovascular Pharmacology;2023-11-30
4. Hereditary transthyretin amyloidosis in the era of RNA interference, antisense oligonucleotide, and CRISPR-Cas9 treatments;Blood;2023-11-09
5. Plasma Pharmacokinetics of N-Acetylgalactosamine-Conjugated Small-Interfering Ribonucleic Acids (GalNAc-Conjugated siRNAs);Clinical Pharmacokinetics;2023-10-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3